Key points are not available for this paper at this time.
Results show that TROP2 is an independent prognostic marker for disease recurrence in intestinal type gastric cancer. Due to its wide distribution TROP2 may become an attractive therapeutic target in a subgroup of patients with gastric cancer.
Mühlmann et al. (Fri,) studied this question.